Incidental finding of non-alcoholic steatohepatitis-cirrhosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,11 MB, PDF-dokument

A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease. The patient was followed at a gastroenterology department due to Crohn’s disease and post-operative bile acid malabsorption. The patient had no symptoms or biochemical findings suggesting liver disease. Surprisingly, a transient elastography (FibroScan®) suggested advanced fibrosis with a median of 16.1 kPa. A liver biopsy showed non-alcoholic steatohepatitis (NASH)-cirrhosis. The diagnosis was only made incidentally and highlights how NASH-cirrhosis may be overlooked due to the lack of symptoms.

OriginalsprogEngelsk
Artikelnummer22-0350
TidsskriftEndocrinology, Diabetes and Metabolism Case Reports
Vol/bind2022
Udgave nummer1
Antal sider5
ISSN2052-0573
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
T A and M H have nothing to declare. F K K has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from the following companies producing and/or developing SGLT2 inhibitors and/or GLP-1RAs mentioned in the manuscript: AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD/Merck, Novo Nordisk and Sanofi. L.L.G, has received honoraria for lectures and/ or presentations, and/or received payments for expert testimony, and/or served on advisory board, and/or received financial support for research from the following companies: Alexion, Gilead, Norgine, Novo Nordisk, Pfizer and Sobi 阀nterntational.

Funding Information:
Grant, Grant no. NNF17OC0027944). The funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.

Funding Information:
This study was funded by Novo Nordisk Foundation (Steno Collaborative

Publisher Copyright:
© 2022 The authors.

ID: 332936281